DigestRedComo funciona
Red
/
Empresas
Te
No verificado

Teva Pharmaceutical Industries Ltd

Sobre qué escribimos

Anuncios brevesFarmacéuticaFinanzasGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

91 Comunicados de prensa

Ver todos los comunicados de prensa
19/03/2026
Farmacéutica
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
19/03/2026
Farmacéutica
Finanzas
Teva Releases Q1 2026 Aide Memoire
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
03/03/2026
Farmacéutica
Finanzas
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
24/02/2026
Farmacéutica
Teva to Present at the Upcoming Investor Conferences in March
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
20/02/2026
Farmacéutica
Anuncios breves
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
17/02/2026
Farmacéutica
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
28/01/2026
Farmacéutica
Gestión empresarial/Administración de Empresas
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
27/01/2026
Farmacéutica
Medicina Salud Bienestar
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
14/01/2026
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0
11/01/2026
Farmacéutica
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Fuente
Teva Pharmaceutical Industries Ltd
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0